Mycoplasma Testing: An Automated Alternative to Traditional NAT Methods
iMICRO 2021 Webinar Series
The standard test for mycoplasma contamination is evolving. As macromolecule drugs derived from mammalian cells become more commonplace, reducing the turnaround time for testing and investigation on the large-scale bioreactors of today has become an indispensable need for manufacturers to ensure productivity and cost competency. The pressure to reduce the turnaround time has spurred innovation with real-time PCR methods. The vision for future testing is simple to use, fast and accurate.
Learn more about how Amgen will boost productivity, by adopting the Next Generation Nucleic Acid Amplification Test (NAT), with Chakameh Azimpour, AMGEN Principal Scientist and our own Jeremy Robertson, bioMérieux Global Solution Manager.
Chakameh AZIMPOUR, Ph.D. Process Development Principal Scientist, Amgen, Thousand Oaks (California, United States)
Jeremy Robertson Global Solution Manager, BIOFIRE, bioMérieux Industrial Microbiology (Chicago, United States)
ACCESS TO THE WEBINAR REPLAY ➔